Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 2
2005 2
2006 3
2007 4
2010 3
2011 2
2012 1
2013 2
2014 3
2015 2
2016 4
2017 5
2018 4
2019 2
2020 2
2021 5
2022 4
2023 1
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

43 results

Results by year

Filters applied: . Clear all
Page 1
Trimebutine suppresses Toll-like receptor 2/4/7/8/9 signaling pathways in macrophages.
Ogawa N, Nakajima S, Tamada K, Yokoue N, Tachibana H, Okazawa M, Oyama T, Abe H, Yamazaki H, Yoshimori A, Sato A, Kamiya T, Yokomizo T, Uchiumi F, Abe T, Tanuma SI. Ogawa N, et al. Among authors: abe t. Arch Biochem Biophys. 2021 Oct 30;711:109029. doi: 10.1016/j.abb.2021.109029. Epub 2021 Sep 10. Arch Biochem Biophys. 2021. PMID: 34517011
Detectable HBV DNA during nucleos(t)ide analogues stratifies predictive hepatocellular carcinoma risk score.
Kaneko S, Kurosaki M, Joko K, Marusawa H, Kondo M, Kojima Y, Uchida Y, Kimura H, Tsuji K, Yagisawa H, Kusakabe A, Kobashi H, Akahane T, Tamaki N, Kirino S, Abe T, Yoshida H, Matsushita T, Hasebe C, Izumi N. Kaneko S, et al. Among authors: abe t. Sci Rep. 2020 Aug 3;10(1):13021. doi: 10.1038/s41598-020-69522-w. Sci Rep. 2020. PMID: 32747646 Free PMC article.
Risk factors for hepatocellular carcinoma at baseline and 1 year after initiation of nucleos(t)ide analog therapy for chronic hepatitis B.
Kaneko S, Kurosaki M, Mashiba T, Marusawa H, Kondo M, Kojima Y, Uchida Y, Fujii H, Akahane T, Yagisawa H, Kusakabe A, Kobashi H, Abe T, Yoshida H, Ogawa C, Furuta K, Tamaki N, Tsuji K, Matsushita T, Izumi N; Japanese Red Cross Liver Study Group. Kaneko S, et al. Among authors: abe t. J Med Virol. 2023 Jan;95(1):e28210. doi: 10.1002/jmv.28210. Epub 2022 Oct 20. J Med Virol. 2023. PMID: 36222204
Trimebutine attenuates high mobility group box 1-receptor for advanced glycation end-products inflammatory signaling pathways.
Nakajima S, Ogawa N, Yokoue N, Tachibana H, Tamada K, Okazawa M, Sato A, Oyama T, Abe H, Kamiya T, Yoshimori A, Yoshizawa K, Inoue S, Yokomizo T, Uchiumi F, Abe T, Tanuma SI. Nakajima S, et al. Among authors: abe t. Biochem Biophys Res Commun. 2020 Dec 17;533(4):1155-1161. doi: 10.1016/j.bbrc.2020.09.126. Epub 2020 Oct 8. Biochem Biophys Res Commun. 2020. PMID: 33041002
A 3-styrylchromone converted from trimebutine 3D pharmacophore possesses dual suppressive effects on RAGE and TLR4 signaling pathways.
Okazawa M, Oyama T, Abe H, Yamazaki H, Yoshimori A, Tsukimoto M, Yoshizawa K, Takao K, Sugita Y, Kamiya T, Uchiumi F, Sakagami H, Abe T, Tanuma SI. Okazawa M, et al. Among authors: abe t. Biochem Biophys Res Commun. 2021 Aug 20;566:1-8. doi: 10.1016/j.bbrc.2021.05.096. Epub 2021 Jun 7. Biochem Biophys Res Commun. 2021. PMID: 34111666
43 results